Abstract
Diabetes mellitus is a heterogenous group of disorders characterised by insulin hyposecretion and insulin insensitivity. Insulin-dependent diabetes mellitus (IDDM) shows predominantly an insulin deficiency whilst insulin insensitivity is the hallmark of non-insulin dependent diabetes mellitus (NIDDM). Hyperglycaemia is the major end result in all forms of diabetes, although many other predictable metabolic defects also occur. These include overproduction of fatty acids and ketone bodies and excessive proteolysis. Hyperglycaemia is of prime importance because of its probable direct relationship to the development of the specific complications of diabetes [22]. The concept of “glucotoxicity” has also arisen recently with respect to inhibitory effects on tissue metabolism [6]. Variations in blood glucose levels also have a major impact on the day-to-day well-being of the diabetic patient.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Blaekshear PJ (1974) Metabolic studies in experimental diabetic ketoacidosis. DPhil Thesis, University of Oxford
Blaekshear PJ, Holloway PAH, Alberti KGMM (1974) The metabolic effects of sodium dich- loroacetate in the starved rat. Biochem J 142: 279–286
Blaekshear PJ, Holloway PAH, Alberti KGMM (1975) The effects of inhibition of gluconeogenesis on ketogenesis in starved and severely diabetic rats. Biochem J 148: 353–362
Bliesath H, Haupt E, Lühmann R, Hoppe FU, Radtke HW (1987) First administration of ETOMOXIR to Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 30: 501A
Chase JFA, Tubbs PK (1972) Specific inhibition of mitochondrial fatty oxidation by 2-bromopalmitate and its co-enzyme A and carnitine esters. Biochem J 129: 55–65
DeFronzo R (1988) The triumvirate, ß-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37: 667–687.
Demaugre F, Leroux J-P, Cartier P (1978) The effects of pyruvate concentration, dichloroacetate and D-cyano-4-hydroxycinnamate on gluconeogenesis, ketogenesis and [3-hydrocybutyrate]/ [3-oxobuytrate] ratios in isolated rat hepatocytes. Biochem J 172: 91–96
DeSilva SR, Betteridge DJ, Shaute JEH, Cudworth AG, Alberti KGMM (1979) Metformin and clofibrate in maturity onset diabetes mellitus: advantages of combined treatment. Diabete Metab 5: 223–239
Ferner R, Rawlins MD, Alberti KGMM (1988) Impaired ß-cell responses improve when fasting blood glucose concentration is reduced in non-insulin-dependent diabetes. Q J Med (New Series) 66: 137–146
Fröhlich J, Wieland O (1971) Glucagon and the permissive action of fatty acids in hepatic gluconeogenesis. Eur J Biochem 19: 557–562
Gerondaes P, Alberti KGMM, Agius L (1988) Interactions of inhibitors of carnitine palmitoyl-transferase I and fibrates in cultured hepatocytes. Biochem J (in press)
Holland PC, Clark MG, Bloxham DP, Lardy HA (1973) Mechanism of action of the hypoglycaemic agent diphenyleneiodonium. J Biol Chem 248: 6050–6056
Jones IR, Miller M, Swai A, Taylor R, Alberti KGMM (1987) Improvement in glucose tolerance by the reduction of lipid concentrations in patients with non-insulin dependent diabetes mellitus ( NIDDM ). Diab Med 4: 563A
Kruszynska YT, Sherratt HSA (1987) Glucose kinetics during acute and chronic treatment of rats with 2[6(4-chlorophenoxy)hexyl]oxirane-2-carboxylate, Etomoxir. Biochem Pharmacol 36: 3917–3921
Randle PJ, Hales CN, Garland PB, Newsholme EA (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet I: 785–789
Reaven GM, Chang H, Ho H, Jeng C-Y, Hoffman BB (1988) Lowering of plasma glucose in diabetic rats by antilipolytic agents. Am J Physiol 254: E23–E30
Schäfer G (1983) Biguanides. A review of history, pharmacodynamics and therapy. Diabete Metab 9: 148–163
Selby PL, Bartlett K, Sherratt HSA, Alberti KGMM (1987) Prolonged inhibition of ketogenesis in man by Etomoxir. Diabetologia 30: 581A
Sherratt HSA, Bartlett K, Bone AJ, Koundakjian PP, Turnbull DM, Osmundsen H, Van Hoof F (1982) Hepatic peroxisomal proliferation caused by ethyl 2[5(4-chloroephenyl)pentyl]oxirane-2- carbocylate (CPOC): a hypoglycaemic inhibitor of mitochondrial fatty acid oxidation. Ann NY Acid Sci 386: 446–448
Sherratt HSA, Bartlett K, Turnbull DM (1983) Four hypoglycaemic compounds that inhibit p- oxidation: 2[5(4-chlorophenyl)pentyl]oxirane-2-carboxylate (POCA), hypoglycin, pent-4-eno- ate and valproate: a comparison of their mechanisms of action. In: Kabara JJ (ed) American Oil Chem Soc, Champaign, II, USA, pp 247–262 (Am Oil Chem Soc Mongr 13 )
Stacpoole PW, Moore G, Korahauser D (1978) Metabolic effects of dichloroacetate in patients with diabetes mellitus and hyperlipoproteinemia. New Engl J Med 298: 526–530
Tchobroutsky G (1978) Relation of diabetic control to development of microvascular complications. Diabetologia 15: 143–152
Turnbull DM, Bartlett K, Younan IM, Sherratt HSA (984) The effects of 2-[5-(4-chlorophenyl)- pentyl]-oxirane-2-carbonyl-CoA on mitochondrial oxidations. Biochem Pharmacol 33: 475–481
Tutwiler GF, Brentzel HJ (1982) Relation of oxidation of long-chain fatty acids to gluconeogenesis in the perfused liver of the guinea pig: effect of 2-tetradecylglycidic acid (McN- 3802). Eur J Biochem 124: 465–470
Tutwiler GF, Dellevigne P (1979) Action of the oral hypoglycaemic agent 2-tetraglycidic acid on hepatic fatty acid oxidation and gluconeogenesis. J Biol Chem 254: 2935–2941
Tutwiler GF, Kirsch T, Mohrbacher R, Ho W (1978) Pharmacologic profile of methyl 2-tetradecylglycidate (McN 3716) - an orally effective hypoglycemic agent. Metabolism 27: 1539–1556
Whitehouse S, Cooper RH, Randle PJ (1974) Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem J 141: 761–774
Wolf HPO, Engel DW (1985) Decrease of fatty acid oxidation, ketogenesis and gluconeogenesis in isolated perfused rat liver by phenylalkyl oxirane carboxylate (B 807-27) due to inhibition of CPTI (EC 2.3.1.21) Eur J Biochem 146: 359–363
Wolf HPO, Eistetter K, Ludwig O (1981) Phenyloxirane carboxylic acids, a new class of hypoglycaemic substances. Diabetologia 21: 344
Wolf HPO, Eistetter K, Ludwig G (1982) Phenylalkyl oxirane carboxylic acids, a new class of hypoglycaemic substances: Hypoglycaemic and hypoletonaemic effects of sodium 2-[5-(4-chloro- phenyl)-pentyl]-oxirane-2-carbocylate (B 807-27) in fasted animals. Diabetologia 22: 456–463
Young JC, Treadway JL, Fades EI, Caslin RF (1986) Effects of oral hypoglycemic agent methylpalmoxirate on exercise capacity of streptozotocin diabetic rats. Diabetes 35: 744–748
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Alberti, K.G.M.M., Sherratt, H.S.A., Selby, P.L. (1989). Metabolic Inhibitors in the Treatment of Diabetes Mellitus. In: Creutzfeldt, W., Lefèbvre, P.J. (eds) Diabetes Mellitus: Pathophysiology and Therapy. Bayer AG Centenary Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74255-2_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-74255-2_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-50506-8
Online ISBN: 978-3-642-74255-2
eBook Packages: Springer Book Archive